Pierre Vandepapelière Email and Phone Number
Pierre Vandepapelière work email
- Valid
Pierre Vandepapelière personal email
- Valid
Pierre Vandepapelière, M.D.,PhD is co-founder, CEO and CMO of Amyl since November 2020. He previously was CEO of Imcyse between 2014 and 2019, transforming an academic research group into a rapidly growing Biotech company developing immunotherapeutics for auto-immune diseases. During that period, he successfully signed partnerships with Pharma industries and raised €35M series B. During the Covid Pandemic, he collaborated on various Covid vaccine projects, in particular with the Rega institute, Leuven, leading to the creation of Astrivax. Before joining Imcyse, Pierre spent 7 years as head of development of immunotherapeutics for auto immune diseases at Neovacs, Paris, and as consultant, he implemented phase IIb programs at Genticel and Abivax. He also has been heading early clinical research at GlaxoSmithKline Biologicals and has extended experience in development of numerous vaccines and therapeutic vaccines worldwide, as well as in the evaluation and use of adjuvants in vaccines. He is currently acting CMO for ACM Biolabs.He graduated in Medicine at the University of Louvain, in Tropical Medicine at the Institute of Tropical Medicine in Antwerp, Belgium and holds a PhD from the University of Gent. When time permits between my large Family ( 5 children and 5 (soon 7) grandchildren) and work, I am passionate by sailing , photography, birdwatching.
-
Chief Executive OfficerAmyl Therapeutics Nov 2020 - PresentBelgiumAmyl therapeutics develops a unique technology platform of rétament of Alzheimer's disease and other neurodegenerative diseases.
-
Consultant In Vaccine And Therapeutic Vaccine DevelopmentVaccibio Consulting Oct 2012 - PresentRégion De Namur, BelgiquePrivate consulting activity to provide clinical development, regulatory and strategic support to Biotech companies and Academic groups in the field of vaccines, therapeutic vaccines for infections, auto-immune diseases, oncology, adjuvants.
-
Chief Medical OfficerImcyse Sa Feb 2016 - Nov 2019Liège Area, Belgium -
CeoImcyse Sa Feb 2015 - Aug 2019BelgiqueIMCYSE is a Biotech company developing a technology platform of immunotherapeutics in multiple indications: auto immune diseases, down regulation of immune response against immunogenic drugs, allergies, etc.Over 4 years, I have built a performing Biotech company from an academic research group in terms of management & governance, organization, strategic prioritization, financing, partnering, preclinical and clinical development, etc.I have recruited the entire management team, and together we have professionalized the organization, and accomplished partnership with 2 leading pharma companies, successfully conducted a phase Ib in type 1 diabetes patients across 7 European countries, obtained multiple grants and completed a series B round of €35M.
-
Vice-President, Chief Medical OfficerNeovacs Sa Jun 2008 - Mar 2015Paris , France• Responsible for clinical development, regulatory affairs, medical affairs, pharmacovigilance, management of contract research organizations • Active involvement in business development, communication, pre-clinical development, assessment of new products, out- and in-licensing opportunities, contacts with investors, the press, big pharmas.• Clinical development of therapeutic vaccines in inflammatory and auto immune diseases• Member of executive management team, Ad hoc member of the Board -
Vice President And Chief Medical OfficerAbivax Mar 2014 - Feb 2015Paris , France -
Head Exploratory Clinical RdGlaxosmithkline Biologicals 2002 - 2008• Core member of strategic, scientific and clinical management executive committees for prioritization of early and future projects, encompassing all aspects of development from pre-clinical to file and commercial valuation• Core member of multidisciplinary teams to evaluate and prepare complete development plans for early phase vaccines and in-licensing opportunities (e.g.: viral and bacterial disease, non infectious diseases new technologies, adjuvants) Organization and leadership of external scientific and medical advisory boards and consultations of local and regional medical affairs, regulatory, clinical and commercial colleagues to support the evaluations.• Clinical development of early phase vaccines and clinical research on adjuvants, mechanisms of action, pathogenesis, delivery platforms, immune responses to vaccination• Clinical expert in adjuvants for advisory boards and safety crisis teams -
Director Clinical RdGlaxosmithkline Biologicals 1990 - 2002• HIV Vaccines and therapeutic vaccines in collaboration with the HVTN, UNAIDS and IAVI. I was leading international teams across the different organizations to drive the set up and conduct of clinical projects• Therapeutic Vaccines - Head of worldwide clinical development of therapeutic vaccines for hepatitis B, Herpes Simplex virus and human papilloma viruses. • Prophylactic herpes simplex vaccine Leader of a clinical program with 15000 subjects in 100 centers worldwide (USA, Canada, Australia, Europe) up to completion of phase III • Full clinical development of combined DTPw-HBV vaccine (Tritanrix®-HB) and DTPw-HBV-Hib up to registration by the European Agency for the Evaluation of Medicinal Products (EMEA). Phase IV and new development studies with hepatitis B vaccine (Engerix® B and improved formulations)• Early clinical development of acellular pertussis vaccine and haemophilus influenza type B vaccine
Pierre Vandepapelière Skills
Pierre Vandepapelière Education Details
-
Therapeutic Vaccines For Chronic Infectious Diseases -
Institute Of Tropical Medicine In Antwerp (Itm)Tropical Medicine
Frequently Asked Questions about Pierre Vandepapelière
What company does Pierre Vandepapelière work for?
Pierre Vandepapelière works for Amyl Therapeutics
What is Pierre Vandepapelière's role at the current company?
Pierre Vandepapelière's current role is Chief Executive Officer at Amyl Therapeutics.
What is Pierre Vandepapelière's email address?
Pierre Vandepapelière's email address is pi****@****ail.com
What schools did Pierre Vandepapelière attend?
Pierre Vandepapelière attended Université Catholique De Louvain, Ghent University, Institute Of Tropical Medicine In Antwerp (Itm), Université De Namur.
What skills is Pierre Vandepapelière known for?
Pierre Vandepapelière has skills like Clinical Development, Pharmaceutical Industry, Biotechnology, Vaccines, Infectious Diseases, Clinical Trials, Immunology, Pharmaceutics, Life Sciences, Clinical Research, Drug Development, Sciences De La Vie.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial